Advances in Treatment of Transfusion-dependent Lower-risk Myelodysplastic Syndromes
At present, the patients with transfusion-dependent lower-risk myelodysplastic syndromes (MDS) have limited treatment options when erythropoiesis-stimulating agent is ineffective or relapsed. With more understanding of the pathological and molecular genetics characteristics of MDS, the development o...
Main Authors: | FENG Yue, LUO Xingchun, ZHU Yu, LIU Bei |
---|---|
Format: | Article |
Language: | zho |
Published: |
Magazine House of Cancer Research on Prevention and Treatment
2021-04-01
|
Series: | Zhongliu Fangzhi Yanjiu |
Subjects: | |
Online Access: | http://html.rhhz.net/ZLFZYJ/html/8578.2021.20.1020.htm |
Similar Items
-
Rapidly Progressive Pancreatic Lipomatosis in a Young Adult Patient with Transfusion-dependent Myelodysplastic Syndrome
by: Wei-Ching Lin, et al.
Published: (2007-08-01) -
Clinical Efficacy of Chelation Therapy in Patients with Low-Risk Myelodysplastic Syndrome
by: SV Gritsaev, et al.
Published: (2019-03-01) -
The role of magnetic resonance imaging in the evaluation of transfusional iron overload in myelodysplastic syndromes
by: Emmanouil Petrou, et al.
Published: (2015-08-01) -
Bartonella henselae bacteremia diagnosed post-mortem in a myelodysplastic syndrome patient
by: Marina Rovani Drummond, et al. -
NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES
by: Francesco D'Alò, et al.
Published: (2010-08-01)